Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
News about QIAGEN N.V. (QGEN) centers on its role as a Netherlands-based Sample to Insight company serving life sciences and molecular diagnostics customers worldwide. This news feed aggregates corporate announcements, product updates, regulatory milestones and financial communications directly related to QGEN.
Readers can follow updates on QIAGEN’s five growth pillars: Sample technologies, QIAstat-Dx syndromic testing, QIAcuity digital PCR, QIAGEN Digital Insights (QDI) bioinformatics and QuantiFERON latent tuberculosis testing. Company news often highlights launches and enhancements of automation systems such as QIAcube Connect, QIAsymphony Connect, QIAsprint, QIAmini and EZ2 Connect Fx, as well as new kits like the EZ2 DNA Investigator Sep&Prep Kit for forensic applications.
Regulatory and clinical diagnostics news includes items such as CE-IVDR certification for QIAstat-Dx panels in Europe, U.S. FDA clearance for QIAstat-Dx Rise, and expansions of test menus for respiratory, gastrointestinal and central nervous system infections. These announcements show how QIAGEN positions its platforms in infectious disease and syndromic testing.
Investors and analysts can also track financial and capital markets developments, including quarterly earnings releases furnished on Form 6-K, outlook updates, and capital return actions such as synthetic share repurchase plans that combine direct capital repayments with reverse stock splits. Strategic moves, for example the agreement to acquire Parse Biosciences to expand into single-cell analysis, are another recurring theme in QGEN news.
For users interested in precision oncology, bioinformatics and AI-enabled solutions, QIAGEN’s news includes information on partnerships, new software capabilities within QDI, and integrated Sample to Insight workflows. Bookmark this page to access an organized stream of QGEN-related announcements spanning products, diagnostics, automation, bioinformatics and investor communications.
QIAGEN N.V. (NYSE: QGEN) will announce its fourth quarter and full-year results for 2021 on February 8 at approximately 16:05 EST. A conference call will follow on February 9 at 15:00 Frankfurt time, featuring CEO Thierry Bernard and CFO Roland Sackers. Investors can join via this link or by dialing the respective numbers for the U.S., UK, and Germany.
QIAGEN has launched its QIAwave product line, introducing three nucleic acid extraction kits that significantly reduce environmental waste. The new kits use up to 63% less plastic and 42% less cardboard compared to standard products. This initiative marks a significant move towards sustainability, aiming to decrease plastic packaging waste by an additional 9% in 2022 after a 9.6% reduction in 2021. The company also aims for net-zero carbon emissions by 2050, receiving a top “Prime” rating from ISS ESG for its efforts.
QIAGEN N.V. (NYSE: QGEN) has announced significant enhancements to its QIAstat-Dx syndromic testing solution, aiming to improve testing capacities for pathogens. New tests include a Gastrointestinal panel for U.S. regulatory approval, designed to detect 22 pathogens, and CE-IVD registration for a Meningitis/Encephalitis panel analyzing 15 pathogens. The new QIAstat-Dx Rise platform, launching in mid-2022, features enhanced efficiency with a Smart Drawer system capable of processing up to 160 tests per day. These advancements respond to increased demand for rapid testing amid ongoing health challenges.
QIAGEN N.V. (NYSE: QGEN) has announced the expansion of its QIAcuity digital PCR platform, now offering non-invasive prenatal testing (NIPT) through collaboration with Atila BioSystems and introducing protein analysis capabilities via a partnership with Actome GmbH. The enhancements reduce sample processing time to 2.5 hours and increase multiplexing capabilities. QIAcuity is also highlighted for its application in detecting rare cancer mutations and testing wastewater for SARS-CoV-2. These advancements aim to establish QIAcuity as a new standard in PCR technology.
QIAGEN N.V. (NYSE: QGEN) announced significant expansions to its QuantiFERON franchise, enhancing its tuberculosis detection capabilities and introducing new applications for latent disease detection. The QuantiFERON SARS-CoV-2 assay, launched in December 2021, has received CE marking to measure T-cell responses to COVID-19. Additionally, the QuantiFERON-TB Gold Plus assay now includes more patient groups as approved by the FDA. The QIAreach QuantiFERON-TB test aims to improve TB detection in resource-limited settings and is now approved for public health procurement in over 100 countries.
Denovo Biopharma and QIAGEN announced a collaboration to develop a blood-based companion diagnostic test for patients with diffuse large B-cell lymphoma (DLBCL). This test aims to identify individuals expressing the Denovo Genomic Marker 1 (DGM1), who may respond to Denovo's investigational drug DB102. The development involves a real-time PCR assay for the QIAGEN Rotor-Gene Q MDx instrument, with plans to seek premarket approval from the FDA. Denovo's DB102 is currently in a Phase III trial for DLBCL and glioblastoma multiforme and has received several FDA designations.
QIAGEN has partnered with Denovo Biopharma to develop a blood-based companion diagnostic test for Diffuse Large B-Cell Lymphoma (DLBCL) patients likely to respond to Denovo's investigational drug DB102. The collaboration seeks FDA premarket approval (PMA) alongside the new drug application (NDA) for DB102. This agreement bolsters QIAGEN's precision medicine initiatives and its oncology testing portfolio. The test will detect Denovo Genomic Marker 1 (DGM1), enhancing treatment personalization for DLBCL patients.
QIAGEN has announced the CE marking of its QuantiFERON® SARS-CoV-2 assay, which measures T-cell responses to SARS-CoV-2, enhancing the assessment of immunity post-COVID-19 vaccination. Unlike traditional serology tests, this assay evaluates both CD4+ and CD8+ T-cell responses, providing deeper insights into immune responses. The technology is designed for ease of use, requiring only whole blood and no lymphocyte purification. T-cell responses offer critical information on the immune system's effectiveness against COVID-19 over time.
QIAGEN has received additional FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay on DiaSorin's LIAISON® XS platform. This expands access to automated TB testing solutions across diverse healthcare settings, from small clinics to large hospitals. The QuantiFERON test, a leading interferon-gamma release assay (IGRA), enhances patient care by replacing outdated tuberculin skin tests. The partnership with DiaSorin enhances the ability to meet the rising demand for TB detection, which affects around one-third of the global population.
QIAGEN N.V. (NYSE: QGEN) confirmed that its PCR tests remain effective in detecting SARS-CoV-2 infections amid the emergence of the B.1.1.529 variant from South Africa. The efficacy was validated through data from GISAID and GenBank. QIAGEN’s tests include the artus SARS-CoV-2 Prep&AMp;Amp UM Kit, QIAstat-Dx systems, and NeuMoDx PCR systems, all confirming reliable results against the new variant. The company will continue biweekly surveillance on its tests' performance to adapt to further viral mutations.